The association between body mass index groups and metabolic comorbidities with healthcare and medication costs: a nationwide biobank and registry study in Finland

References

• Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017 Jun;377(1):13–7. DOI:10.1056/NEJMoa1614362.
   PubMed Web of Science ®Google Scholar
• OECD. The Heavy Burden of Obesity. 2019. 240 p.
   Google Scholar
• Kjellberg J, Tange Larsen A, Ibsen R, et al. The socioeconomic burden of obesity. Obes Facts. 2017;10(5):493–502.
   PubMed Web of Science ®Google Scholar
• Vesikansa A, Mehtälä J, Jokelainen J, et al. The association of body mass index with quality of life and working ability: a Finnish population-based study. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2022 Feb;31(2):413–423. 10.1007/s11136-021-02993-0.
   PubMed Web of Science ®Google Scholar
• Goettler A, Grosse A, Sonntag D. Productivity loss due to overweight and obesity: a systematic review of indirect costs. BMJ Open. 2017 Oct;7(10):e014632.
   PubMed Web of Science ®Google Scholar
• Andersson E, Eliasson B, Steen Carlsson K. Current and future costs of obesity in Sweden. Health Policy. 2022;126(6):558–564.
   PubMed Web of Science ®Google Scholar
• Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet Lond Engl. 2011 Aug;378(9793):815–825.
   PubMed Web of Science ®Google Scholar
• Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223.
   PubMed Web of Science ®Google Scholar
• Hugh Waters and Marlon Graf, America’s Obesity Crisis The Health and Economic Costs of Excess Weight. Milken Institute. 2018. https://milkeninstitute.org/sites/default/files/reports-pdf/Mi-Americas-Obesity-Crisis-WEB_2.pdf
   Google Scholar
• Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 Mar;6(3):237–248.
   PubMed Web of Science ®Google Scholar
• Ahmad NN, Robinson S, Kennedy-Martin T, et al. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obes Rev Off J Int Assoc Study Obes. 2021 Nov;22(11):e13326.
   Google Scholar
• Webber L, Divajeva D, Marsh T, et al. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open. 2014 Jul;4(7):e004787. 10.1136/bmjopen-2014-004787.
   PubMed Web of Science ®Google Scholar
• Koponen P, Borodulin K et al. Terveys, toimintakyky ja hyvinvointi Suomessa FinTerveys 2017 - tutkimus. Finnish Institute for Health and Welfare. 2018 [cited 2023 Jan 13]. Avilable from:http://urn.fi/URN:ISBN:978-952-343-105-8
   Google Scholar
• Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, E. Expert Panel on DetectionEvaluation, and treatment of high blood cholesterol in adults. executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detectionEvaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA2001 May 1628512486–249710.1001/jama.285.19.2486
   Google Scholar
• Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011 [Internet]. 2014 [cited 2022 Jun 28]. Available from: https://www.julkari.fi/handle/10024/114683
   Google Scholar
• Borodulin K, Sääksjärvi K. FinHealth 2017 Study: Methods. Finnish Institute for Health and Welfare. 2019 [cited 2023 Jan 13]. Avilable from: http://urn.fi/URN:ISBN:978-952-343-449-3
   Google Scholar
• Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures in adults. Int J Obes. 2005;29(3):334–339.
   Web of Science ®Google Scholar
• Yates N, Teuner CM, Hunger M, et al. The economic burden of obesity in Germany: results from the population-based KORA studies. Obes Facts. 2016;9(6):397–409. DOI:10.1159/000452248
   PubMed Web of Science ®Google Scholar
• Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021 Mar;27(3):354–366. 10.18553/jmcp.2021.20410.
   PubMed Web of Science ®Google Scholar
• Ward ZJ, Bleich SN, Long MW, et al. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE. 2021 Mar;16(3):e0247307.
   PubMed Web of Science ®Google Scholar
• Kent S, Green J, Reeves G, et al. Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study. Lancet Public Health. 2017 May;2(5):e214–22. 10.1016/S2468-2667(17)30062-2.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Malone DC, Raebel MA, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009 Aug;7(4):305–314. 10.1089/met.2008.0070.
   PubMed Web of Science ®Google Scholar
• Vesikansa A, Mehtälä J, Mutanen K, et al. Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study. Eur J Health Econ. [2022 Sep 5[cited 2022 Nov 30]; Available from]. Internet. DOI:10.1007/s10198-022-01507-0
   Web of Science ®Google Scholar
• Kent S, Fusco F, Gray A, et al. Body mass index and healthcare costs: a systematic literature review of individual participant data studies. Obes Rev Off J Int Assoc Study Obes. 2017 Aug;18(8):869–879.
   Google Scholar
• Connor Gorber S, Tremblay M, Moher D, et al. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obes Rev off J Int Assoc Study Obes. 2007 Jul;8(4):307–326.
   Google Scholar
• Fujiyoshi A, Murad MH, Luna M, et al. Metabolic syndrome and its components are underdiagnosed in cardiology clinics. J Eval Clin Pract. 2011 Feb;17(1):78–83. 10.1111/j.1365-2753.2010.01371.x.
   PubMed Web of Science ®Google Scholar
• Kim EG, Kaelber DC. Phenotypic prevalence of obesity and metabolic syndrome among an underdiagnosed and under screened population of over 50 million children and adults. Front Genet InternetAvailable from. 2022 [cited 2022 Dec 2]; 13. 10.3389/fgene.2022.961116.
   Web of Science ®Google Scholar
• Buss J. Limitations of body mass index to assess body fat. Workplace Health Saf. 2014 Jun;62(6):264.
   PubMed Web of Science ®Google Scholar
• Bray GA, Kim KK, Wilding JPH. Federation on behalf of the WO. obesity: a chronic relapsing progressive disease process. A position statement of the world obesity federation. Obes Rev. 2017 Jul;18(7):715–723.
   PubMed Web of Science ®Google Scholar